Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Newly Diagnosed CML-AP
NCT01605981Phase 4Withdrawn
- Sponsor
- Novartis
- Start
- Feb 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoints: Safety and tolerability profile of nilotinib at 12 months and Efficacy of nilotinib 400 mg BID at 12 months. Planned start Feb 2014; status: withdrawn.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01605981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605981.